@iduncan @loriara @rachelweinerwp @abtran Operations manager at DCA said FAA rejected plans to slow arrivals. “DCA is a very political airport, he said. “We were told it was too political”

Gift link to article by @iduncan @loriara @rachelweinerwp @abtran

My @washingtonpost colleagues have not stopped digging into why a plane and helicopter collided at DCA airport, killing 67. And the revelations are chilling

If you are 65+ and thinking about getting a coronavirus shot, this week might be your best opportunity. Right now, the FDA has approved updated vaccines for that age group. But it’s possible it could get much tougher to get those shots next week. 1/3

When ICE inspectors toured the giant new Fort Bliss tent camp for migrants, built in under two months, they found 60 violations of federal detention standards, many of which directly impacted the safety of workers and detainees, we reported today in @washingtonpost.com 🧵-->

The GLP-1 microdosing wellness and longevity craze without any data for dose or evidence of effect gift link https://t.co/mRfEOL6xlR @ByDanielGilbert

I wonder if they are microdosing GLP-1s too…

https://t.co/DrmID4JezE

Was not expecting Chevron’s CEO to plug his diversity and inclusion efforts in response to what Chevron does better than Exxon

Who could’ve predicted? Oh wait, the @seattletimes back in 2021:

NEW: The CDC shooting was much worse than initially reported. 181 rounds. 150 windows hit. Staff are furious at RFK Jr. and Trump becuz their long-running fears about anti-vax rhetoric turning deadly seem to be vindicated. ⁦@LaurenWeberHP⁩ + Me.

Friends, a note about me and The Washington Post: I'm staying. I say that because in a season of buyouts, a number of my great colleagues are departing this month and numerous people have reached out to ask if I am, too. I am not. I'm staying because even after some body

Here’s a link to read the article for free: https://t.co/951OmZsKYe 6/6

And that’s where things stood when I called Tim to fact-check the article. Ask yourself, as I did, if he’s doing great under these circumstances, how am I doing? (5/6)

After a third death from a different Sarepta gene therapy, the FDA requested that Sarepta stop all dosing of its gene therapy for Duchenne, the biggest driver of its revenue. The company refused, only to blink 3 days later and agree to the FDA’s request. 4/6

I got in touch with Tim after two teens with Duchenne died following a gene therapy — the medicine that has anchored the Revells’ hopes. The company that makes the drug stopped dosing patients in advanced stages Duchenne, like Andrew and Timothy. Then things got worse… 3/6

He is the father of two beautiful sons, Timothy (21) and Andrew (18). They have a rare, fatal disease that is destroying their muscles. The median survival age for Duchenne muscular dystrophy is about 28. Here they are at home (📷 Sergio Flores) 2/6

A story about a story - I called a sales executive in Texas named Tim Revell on Friday to fact check a story, and I’m still thinking about what he said when I asked how he was doing. “I’m doing GREAT" Here’s something to know about Tim:

Gift link:

Sometimes a historical grace note hits hard, as in this scoop by @dmac1 @SilviaElenaFF on ICE mandating ankle monitoring for immigrants